Everest Organics Ltd.
BSE: EVERESTO · Pharmaceuticals · sector
₹242.25BSE close 2026-10-26
Key numbers
Market cap₹235 cr
Price₹242.25
52w high / low₹536 / ₹197
P/E40.2xSector median 27.9x
P/B3.1xSector median 2.9x
Book value₹77.8
Dividend yield–Sector median 0.48%
ROE7.2%Sector median 11.7%
ROCE11.4%Sector median 12.3%
OPM10.3%Sector median 14.0%
Debt / equity0.66xSector median 0.16x
EV/EBITDA14.4xSector median 18.6x
Interest cover2.1x
Current ratio1.10x
Sales growth 3y+2.3%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹1 cr vs borrowings ₹50 cr (FY26): borrowings are higher by ₹49 cr.
- Operating profit covered interest 2.1x in the last 12 months.
- Other income was 21% of net profit in the last 12 months.
- Dividend paid in 2 of the last 5 financial years.
- Price ₹242.25 on 2026-10-26: -54.8% from the 52-week high, +23.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹517.75 · low ₹114.85
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 41 | 54 | 51 | 43 | 49 | 48 |
| EBITDA | 3 | 4 | 5 | 4 | 7 | 4 |
| OPM % | 8.4% | 8.3% | 10.1% | 8.3% | 13.7% | 8.9% |
| Other income | 0 | 1 | 0 | 0 | 0 | 0 |
| Net profit | 3 | 1 | 1 | 0 | 3 | 1 |
| EPS (₹) | 1.35 | 1.45 | 1.19 | 0.99 | 2.69 | 1.15 |
| Revenue YoY | +19.1% | -10.0% | ||||
| Profit YoY | -9.6% | -21.3% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 200 | 183 | 197 | 159 | 196 | 191 |
| EBITDA | 6 | 1 | 11 | 7 | 20 | 20 |
| Net profit | 1 | -0 | 0 | -1 | 6 | 5 |
| EPS (₹) | 1.43 | -0.23 | 0.17 | 2.97 | 5.70 | 6.02 |
| Revenue growth | -8.5% | +7.8% | -19.1% | +23.0% | – | |
| Profit growth | -115.8% | – | -1,021.4% | – | – | |
| Dividend / share (₹) | 1.00 | 0.50 | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +2.3% | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | +39.5% (2y) | -40.4% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 70 | 75 |
| Borrowings | 48 | 50 |
| Cash & equivalents | 7 | 1 |
| Total assets | 224 | 240 |
| Fixed assets | 48 | 44 |
| Capital work in progress | 21 | 21 |
| Investments | 0 | 0 |
| Receivables | 88 | 116 |
| Inventory | 45 | 45 |
| Payables | 96 | 89 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -5 | 4 |
| Cash from investing | -5 | -2 |
| Cash from financing | 16 | -8 |
| Capex | 4 | 5 |
| Free cash flow | -9 | -0 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -1.8% | 7.3% |
| ROCE % | 1.7% | 11.6% |
| Debtor days | 202 | 216 |
| Inventory days | 168 | 133 |
| Payable days | 355 | 264 |
| Cash conversion cycle (days) | 15 | 85 |
| Working capital days | 18 | 28 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| EVERESTO | ₹235 cr | 40.2x | 3.1x | 7.2% | 11.4% | 10.3% | +2.3% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2022-09-15 | Dividend | Final Dividend Rs 0.5 |
| 2021-09-08 | Dividend | Final Dividend Rs 1.0 |
| 2021-02-17 | Dividend | Interim Dividend Rs 0.5 |
| 2020-09-01 | Dividend | Final Dividend Rs 1.0 |
| 2019-09-03 | Dividend | Dividend Rs 1.0 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | EVERESTO |
| BSE code | 524790 |
| ISIN | INE334C01029 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.